Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

Summary

This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes.

The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.

Conditions

• Parkinson Disease

Interventions

DRUG

DaTscan

Sponsors & Collaborators

• Institute for Neurodegenerative Disorders

  collaborator OTHER

• Ken Marek, MD

  lead OTHER

Principal Investigators

• Kenneth L Marek, MD · Institute for Neurodegenerative Disorders

• John Q. Trojanowski, MD, PhD · University of Pennsylvania

• Arthur W. Toga, PhD · University of California, Los Angeles

• Tatiana Froud, PhD · Indiana University

• Karl Kieburtz, MD · Clinical Trials Coordination Center

• Andrew Singleton, PhD · Laboratory of Neurogenetics; National Institute on Aging NIH

• John P Seibyl, MD · Institute for Neurodegenerative Disorders

• Christopher Coffey, PhD · Clinical Trials Statistical and Data Management Center, University of Iowa

Study Design

Allocation

NA

Purpose

OTHER

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

30 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-06-30

Primary Completion

2020-06-30

Completion

2020-06-30

Countries

• United States
• Australia
• Austria
• France
• Germany
• Greece
• Israel
• Italy
• Norway
• Spain
• United Kingdom

Study Locations